In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Main Results of the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin or Resistance to clopidogrel study (3T/2R).

Hot Line III



Presenter report

Valgimigli, Marco (Italy)

Webcast

Inhibition of platelet aggregation following an intake of aspirin or clopidogrel varies greatly among patients, and previous studies have shown that poor response to oral antiplatelet agents increases the risk of thrombotic events, especially after coronary angioplasty.  It was previously unknown if this reflected suboptimal platelet inhibition per se, which might benefit from alternative or more potent antiplatelet agents.

Enrolled in the study were 263 patients (out of 1277 who were initially screened) who were poor responders to aspirin and/or clopidogrel, based on a point-of-care assay, who underwent elective coronary angioplasty at ten European sites for stable or low-risk unstable coronary artery disease.  Patients were randomly assigned in a double blind manner to receive either high-dose bolus (HDB) tirofiban or placebo on top of standard aspirin and clopidogrel therapy. 

The primary end point was the occurrence of periprocedural myocardial infarction, as defined by an increase in Troponin I or T greater than 3 times the upper limit of normal within 48 hours, which is in keeping with the universal definition of myocardial infarction consensus document. This was attained in 20.4 percent of patients treated with HDB tirofiban, compared to 35.1 percent of patient treated with placebo.  This resulted in a significant reduction of major adverse cardiovascular events within 30 days in the HDB tirofiban group compared to the placebo group (21.2 percent versus 36.6 percent, respectively; p=0.0065).  The incidence of bleeding was low and did not differ between the two groups.


These findings are significant in that we demonstrate a proof of concept for a new treatment strategy in a patient segment whose needs have so far remained unaddressed – managing for the increased risk of thrombotic events due to non-responsiveness of patients to standard oral antiplatelets such as aspirin or clopidogrel.


Discussant :

Verheugt, Freek (NetherlaWatch webcastds)

Webcast

Slides available

References


3210-3211

SessionTitle:

Hot Line Update III

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.